UTI treatment Pivya now available in US. www.empr.com/news/pivya-n...

The strongest factors for childhood food allergies are allergic rhinitis and wheeze. www.empr.com/news/risk-fa...

Investigational treatment alongside daratumumab and dexamethasone looks promising for in patients with relapsed or refractory multiple myeloma. www.empr.com/news/fda-gra...

Symptoms of treatment-resistant depression were significantly reduced at week 6 of treatment with psilocybin 25mg. www.empr.com/news/synthet...

🎧 New Weekly Dose Pod! This week: 💉 Hep B birth dose found safe and effective despite CDC change; ✅ Treatments approved for pancreatic and ovarian cancer; and 😴 FDA to review investigational treatment for narcolepsy. www.empr.com/news/mpr-wee...

Optune Pax is a portable medical device that delivers TTFields non-invasively via wearable arrays to disrupt electrical processes essential for cancer cell division. www.empr.com/news/fda-app...

The American Medical Association announced that they are creating an independent system to review scientific evidence on vaccines. www.empr.com/news/ama-lau...

The plea from Oz was the most forceful yet for vaccination from an administration that has repeatedly expressed skepticism about vaccine safety and effectiveness. www.empr.com/news/dr-oz-u...

The FDA have given Priority Review to a potentially new treatment for narcolepsy. www.empr.com/news/fda-gra...

Lowering the cost by 18% or making the current cash price available to all patients would make semaglutide cost-effective, study finds. www.empr.com/news/seconda...

View all the drugs the FDA are due to decide upon in March, all in one place on MPR. www.empr.com/news/fda-dru...

Just two days after introducing the pill, Hims has stopped selling it. www.empr.com/news/hims-pu...

While they say most gender-related surgeries for minors should be postponed until adulthood, the AMA stressed it still supports access to gender-related care for young people. www.empr.com/news/america...

Updated FDA labeling for Yescarta now includes patients with relapsed or refractory primary CNS lymphoma, expanding treatment options for this group. www.empr.com/news/yescart...

🎧 New MPR Weekly Dose Podcast! 🔹 Combo Tx aims to be next to enter weight loss space; 🔸 Amgen refuse to remove drug from market; ⚖️ Novo Nordisk threaten Hims & Hers; 🔸 Oral film sildenafil approved; and 🔸 NDA accepted for mCRC treatment. www.empr.com/news/mpr-wee...

“The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety,” Novo Nordisk said in a statement. www.empr.com/news/novo-no...

Amgen refuses to remove Tavneos from the US market. In a letter to health care providers, Amgen stated it was “not aware of any issues with the underlying patient data.” www.empr.com/news/amgen-d...

AstraZeneca has already provided the requested info to the FDA and a decision on the updated BLA is expected in the first half of 2026. www.empr.com/news/decisio...

🎧 Catch up with this week's pharma news on the MPR Pod: 💊 Prenatal acetaminophen use not linked to autism risk; 🦟 Ixchiq withdrawn; 🔹 Nexplanon Use Extended; 🔸 Suicidal ideation warning removed from GLP-1s; 😞 At-home device for MDD. www.empr.com/news/mpr-wee...

💊💉 ICYMI: Catch up with all the newly approved treatments that occurred 2025 with MPR's comprehensive breakdown listed by therapeutic category. www.empr.com/news/2025-fd...

With a median follow-up of 12 months, the unconfirmed overall response rate was 40%, with 4 complete responses and 2 partial responses. www.empr.com/news/fda-gra...

Previously, the prevention of pregnancy treatment was only approved for use for up to 3 years. www.empr.com/news/nexplan...

Chikungunya vaccine license application withdrawn after serious adverse event outside of the US. www.empr.com/news/valneva...

🎧 On the latest MPR Pod we sit down with US News and World Report's Annika Urban to discuss the top health trends for 2026. Available where ever you get your podcasts from or directly on MPR: www.empr.com/news/mpr-wee...

📢 Latest MPR Pod out now! We sat down with US News and World Report's Annika Urban to discuss the top health trends for 2026. Listen now! www.empr.com/news/mpr-wee...

The court said the cuts may have been retaliation for the group speaking out against the federal government. www.empr.com/news/judge-o...

In 2025 the FDA approved a wide range of therapies, view them all on MPR, listed by therapeutic category. www.empr.com/news/2025-fd...

Manufacturers to remove suicidal ideation warnings from Saxenda, Wegovy, and Zepbound labels following a large-scale FDA safety investigation. www.empr.com/news/fda-fin...

Study suggests GLP-1 use may optimize psoriatic arthritis outcomes. www.empr.com/news/tirzepa...

Drawing backlash from multiple medical organizations, the CDC website has been updated to suggest a vaccine-autism link. In his January confirmation hearing RFK Jr said he would not impose his personal antivax views. ➡️ www.empr.com/news/medical...

Tonmya (cyclobenzaprine HCl sublingual tablets) is now commercially available, the first new FDA-approved fibromyalgia treatment in over 15 years. #Fibromyalgia #DrugApprovals #NewDrug www.empr.com/news/fibromy...

October 2025 Drug Approvals: Our at-a-glance essential prescribing update. ➡️ www.empr.com/news/october...

The FDA has fully approved Komzifti (ziftomenib), the first and only once-daily oral menin inhibitor, for adults with R/R NPM1-mutated AML. www.empr.com/news/komzift...

Get yourself up to date on Lynkuet — a treatment approved for vasomotor symptoms due to menopause — with our InsightRx interview with trial investigator Dr JoAnn Pinkerton. www.empr.com/news/lynkuet...

Law feature: This month's case resulted in a jury finding in favor of the patient to the tune of $40 million dollars and apportioned the pharmacist's fault at 2%. www.empr.com/features/dos...

Lynkuet was recently approved to treat vasomotor symptoms due to menopause, hear all about it in our interview with one of the trial investigators in our latest InsightRx! www.empr.com/news/lynkuet...

Current evidence for the use of leucovorin to treat autism symptoms is mainly limited to small studies and case reports in children with CFD. www.empr.com/news/aap-cur...

From ACR 2025: biologic disease-modifying antirheumatic drugs (DMARDs) appear to be tied to worse COVID-19 outcomes than conventional DMARDs. www.empr.com/reports/biol...

This Class II Neutrogena recall involves 1312 cases of the 50-count, 25-pack towelettes. www.empr.com/news/neutrog...

Prefilled single-dose autoinjector now available for treatment of migraine and cluster headache. www.empr.com/news/brekiya...

🎧 Latest MPR Pod out now! 🔹 Label changes for tranexamic acid; 🔸 New approval for Tezspire; 🔹 Psychedelic gains Breakthrough Tx status for depression; 🔸 Oral semaglutide approved to reduce MACE risk in T2DM; and 🔹 Gazyva approved for lupus nephritis. www.empr.com/news/mpr-wee...

Findings showed the study did not meet its primary endpoint of preventing CMV infection in seronegative participants. www.empr.com/news/moderna...

Tylenol maker urges regulators to not add autism warning to label citing a lack of scientific evidence. www.empr.com/news/fda-and...

Drug combo gets Priority Review for possible adjuvant treatment in patients with muscle-invasive bladder cancer. www.empr.com/news/enfortu...

There have been continued reports of tranexamic acid being erroneously administered resulting in serious harm and prompting this label change. www.empr.com/news/fda-adm...

Participants in a social anxiety treatment trial were tasked with delivering a 5 minutes speech with 2 minutes notice. The results did not match the primary endpoint. www.empr.com/news/negativ...

From 2005 to 2024, an estimated 3,112 pickleball-related ocular injuries occurred, with 1,262 injuries occurring in 2024 alone. www.empr.com/news/pickleb...

A psychedelic nasal spray has been designated a Breakthrough therapy by the FDA. www.empr.com/news/intrana...

Jascayd was recently approved to treat idiopathic pulmonary fibrosis, we spoke to one of the trial investigators it in our latest InsightRx. www.empr.com/news/jascayd...

📢 Latest MPR Podcast out now! 🔹 New treatment approved for bipolar I disorder; 🔸 Rinvoq IBD indications updated; 🔴 Blood-based test for early detection of amyloid pathology; and 💊 Oral GLP-1 treatment continues to show promise in T2D. www.empr.com/news/mpr-wee...